Publications
291
Citations
5,335
Est. group size
—
Recurring co-author estimate
Active years
40
Publishing since 1986
Thomas A. Gardner conducts clinical research in urologic oncology, focusing on the treatment of prostate cancer. Recent work includes clinical trials of immunotherapy (such as the vaccine Sipuleucel-T combined with hormone-blocking drugs) for advanced prostate cancer, as well as minimally invasive approaches like MRI-guided ultrasound ablation to destroy localized prostate tumors.
Publication activity has been variable over the past decade, with a large spike in 2023 driven mainly by supplementary trial materials and lower output in the most recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Which Tissue is the Issue? A Meandering Path to Diagnosis
American Journal of Respiratory and Critical Care Medicine · 2025
- PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 5-YEAR FOLLOW UP
Urologic Oncology Seminars and Original Investigations · 2024
- Supplementary Figure 3 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Materials and Methods, Tables ST1-13 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
2023
- Supplementary Figure 2 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Figure 1 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Tables 1-3, Figure Legends from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Figure 3 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Figure 2 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Figure 1 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Materials and Methods, Tables ST1-13 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
2023
- Supplementary Figure SF1 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
2023
- Supplementary Figure SF2 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
2023
- Data from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- Data from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
2023
- The Journal of Urology×10
- Journal of Clinical Oncology×4
- Urologic Oncology Seminars and Original Investigations×3
- Frontiers in Marine Science×2
- Journal of Endourology×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile